BCR E3 Ubiquitin Ligase Complex: A Drug Target for Cancer and Neurodegenerative Diseases

Target Name: BCR(KLHL22) E3 ubiquitin ligase complex

NCBI ID: P25398

BCR(KLHL22) E3 ubiquitin ligase complex

Other Name(s): BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex

BCR E3 Ubiquitin Ligase Complex: A Drug Target for Cancer and Neurodegenerative Diseases

The BCR (KLHL22) E3 ubiquitin ligase complex is a protein complex that plays a crucial role in the regulation of gene expression and protein degradation in the cell. The BCR E3 ubiquitin ligase complex is composed of three subunits: BCR (KLHL22), ubiquitin, and E2 ubiquitin. The BCR E3 ubiquitin ligase complex is responsible for the ubiquitination of various protein targets, including histone proteins, transcription factors, and intracellular signaling proteins.

The BCR E3 ubiquitin ligase complex is a well-established target for drugs that are used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for the success of these drugs is their ability to inhibit the activity of the BCR E3 ubiquitin ligase complex, leading to the degradation of target proteins and a decrease in the levels of these proteins in the cell.

The BCR E3 ubiquitin ligase complex is composed of three subunits that work together to achieve its function: BCR (KLHL22), ubiquitin, and E2 ubiquitin. BCR (KLHL22) is the catalytic subunit of the complex, while ubiquitin and E2 ubiquitin serve as subunit 2 and subunit 3, respectively.

The BCR E3 ubiquitin ligase complex uses a specific ubiquitination mechanism to target its protein targets. Ubiquitin is a small protein that plays a critical role in the regulation of protein stability and dynamics. It can bind to specific amino acid residues on target proteins and help to stabilize them by forming a covalent bond with a specific amino acid residue. The BCR E3 ubiquitin ligase complex uses ubiquitin to create a covalent complex with its protein targets.

Once the BCR E3 ubiquitin ligase complex has bound to a protein target, it works to ubiquitinate this protein. This involves the formation of a covalent bond between ubiquitin and the target protein, which results in the Target protein being ubiquitinated. Once the target protein is ubiquitinated, it is then targeted for degradation by the BCR E3 ubiquitin ligase complex.

The BCR E3 ubiquitin ligase complex plays a crucial role in the regulation of gene expression and protein degradation in the cell. It is involved in the ubiquitination of various protein targets, including histone proteins, transcription factors, and intracellular signaling proteins. The BCR E3 ubiquitin ligase complex is a drug target (or biomarker) that can be targeted by small molecules, including anti-cancer drugs, small molecules that interfere with protein stability, and antibodies that recognize and bind to specific ubiquitin subunits.

In conclusion, the BCR (KLHL22) E3 ubiquitin ligase complex is a protein complex that plays a critical role in the regulation of gene expression and protein degradation in the cell. It is composed of three subunits: BCR (KLHL22), ubiquitin, and E2 ubiquitin, and it uses a specific ubiquitination mechanism to target its protein targets. The BCR E3 ubiquitin ligase complex is a drug target (or biomarker) that can be targeted by small molecules, including anti-cancer drugs, small molecules that interfere with protein stability, and antibodies that recognize and bind to specific ubiquitin subunits. Further studies on the BCR E3 ubiquitin ligase complex have the potential to provide new insights into the regulation of gene expression and protein degradation in the cell and may lead to the development of new treatments for various diseases.

Protein Name: BCR(KLHL22) E3 Ubiquitin Ligase Complex

The "BCR(KLHL22) E3 ubiquitin ligase complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCR(KLHL22) E3 ubiquitin ligase complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets